Segmental Reporting

12 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure

24.       Segmental reporting

Shire comprises a single operating and reportable segment engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs.

This segment is supported by several key functions: a Pipeline group, consisting of R&D and Corporate Development, which prioritizes its activities towards late-stage development programs across a variety of therapeutic areas, while focusing its pre-clinical development activities primarily in Rare Diseases; a Technical Operations group responsible for the Company's global supply chain; and an In-line marketed products group focuses on commercialized products. The In-Line marketed products group has commercial units that focus exclusively on the commercial execution of its marketed products including in the areas of Rare Diseases, Neuroscience, and GI and Internal Medicine, and to support the development of our pipeline candidates, in Ophthalmics. This ensures that the Company provides innovative treatments, and services the needs of its customers and patients, as efficiently as possible. The business is also supported by a simplified, centralized corporate function group. None of these functional groups meets all of the criteria to be an operating segment.

This single operating and reportable segment is consistent with the financial information regularly reviewed by the Executive Committee (which is Shire's chief operating decision maker) for the purposes of evaluating performance, allocating resources, and planning and forecasting future periods.

Geographic information

Revenues (based on the geographic location from which the sale originated):

	2014	2013	2012
Year to December 31,	$’M	$’M	$’M
	___________	___________	___________
Ireland	18.5	22.5	20.6
United Kingdom	201.4	206.7	207.0
North America	4,354.8	3,386.2	3,006.1
Rest of World	1,447.4	1,318.9	1,293.7
	____________	____________	____________
Total revenues	6,022.1	4,934.3	4,527.4
	____________	____________	____________

Long-lived assets comprise all non-current assets, (excluding goodwill and other intangible assets, deferred contingent consideration assets, deferred tax assets, investments and financial instruments) based on the geographic location within which the economic benefits arise:

	2014	2013
Year to December 31,	$’M	$’M
	___________	___________
Ireland	3.1	5.8
United Kingdom	67.4	70.3
North America	750.4	802.9
Rest of World	23.3	13.8
	____________	____________
Total	844.2	892.8
	____________	____________

Material customers

In the periods set out below, certain customers accounted for greater than 10% of the Company's product revenues:

	2014	2014	2013	2013	2012	2012
Year to December 31,	$’M	% product revenue	$’M	% product revenue	$’M	% product revenue
	___________	___________	___________	___________	___________	___________
McKesson Corp.	1,021.0	18	902.9	19	835.9	20
Cardinal Health Inc.	979.9	17	853.7	18	1,035.7	24
AmerisourceBergen Corp	759.2	13	721.0	15	307.4	7
	____________	___________	____________	___________	____________	___________
Amounts outstanding as at December 31, in respect of these material customers were as follows:
					2014	2013
December 31,					$’M	$’M
					___________	___________
McKesson Corp.					179.4	161.3
Cardinal Health Inc.					164.5	149.5
AmerisourceBergen Corp					134.9	164.6
					____________	___________

In the periods set out below, revenues by major product were as follows:

	2014	2013	2012
	$’M	$’M	$’M
	___________	___________	___________
VYVANSE	1,449.0	1,227.8	1,029.8
LIALDA/MEZAVANT	633.8	528.9	399.9
ELAPRASE	592.8	545.6	497.6
CINRYZE	503.0	-	-
REPLAGAL	500.4	467.9	497.5
ADDERALL XR	383.2	375.4	429.0
VPRIV	366.7	342.7	306.6
FIRAZYR	364.2	234.8	116.3
INTUNIV	327.2	334.9	287.8
PENTASA	289.7	280.6	265.8
FOSRENOL	183.0	183.4	172.0
XAGRID	108.5	99.4	97.2
Other product sales	128.9	136.1	153.4
	____________	____________	____________
Total product sales	5,830.4	4,757.5	4,252.9
	____________	____________	____________